Biotech entity
Every one of those 2 sits in a single category, pharma. PepGen is most often covered alongside Freightos, which appears in 1 of these 2 stories. The 13-day window averages about 1.1 stories each week. They are less corroborated than the beat average, carrying 2.5 original sources each against 3.3 for the same window.
Last mentioned: Mar 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, pharma. PepGen is most often covered alongside Freightos, which appears in 1 of these 2 stories. The 13-day window averages about 1.1 stories each week. They are less corroborated than the beat average, carrying 2.5 original sources each against 3.3 for the same window. The 5 average consequence score is below the beat benchmark of 5.9 in the same window. We currently track 2 Biotech stories that mention PepGen, published between February 21, 2026 and March 5, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 123 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering PepGen. Shared-story counts are live from our verified record — not editorial picks.
OmniAb and PepGen have released their full-year 2025 financial results, highlighting a period of operational scaling and clinical advancement. While OmniAb continues to expand its antibody discovery ecosystem, PepGen is entering a critical phase with key data readouts expected in 2026 for its neuromuscular pipeline.
GeneDx (WGS) and PepGen (PEPG) are scheduled to release financial results on Monday, marking a pivotal moment for the clinical genomics and neuromuscular therapeutic sectors. Investors are looking for GeneDx to demonstrate a sustainable path to profitability through its whole genome sequencing volume, while PepGen's update will focus on its clinical pipeline and cash position.
PepGen is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
